Skip to main content

Advertisement

SpringerLink
Log in

Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs

  • Comment
  • Published:
Eye Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ranibizumab similar biologic launched in India. https://www.gabionline.net/biosimilars/news/Ranibizumab-similar-biologic-launched-in-India. Accessed July 23, 2022

  2. Sharma A, Loewenstein A, Kuppermann BD. The future of biosimilar and biobetters in Ophthalmology. touchREVIEWS Ophthalmol. 2022;16:6–7.

    Article  Google Scholar 

  3. Apsangikar P, Ghadge P, Naik M, Nair S, Payghan R. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087–95.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Singh R, Chauhan R, Saxena A, Shah A, Mondal L, Bakhle D, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70:3008–14.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye. 2020;34:1006–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine.

Author information

Authors and Affiliations

  1. Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India

    Ashish Sharma

  2. Madhavi Netralaya, Ara, Bihar, India

    Nilesh Kumar

  3. Sankara eye Hospital, Coimbatore, TN, India

    Nikulaa Parachuri

  4. University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy

    Francesco Bandello

  5. Division of Ophthalmology, Tel Aviv Medical University, Tel Aviv, Israel

    Anat Loewenstein

  6. Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA

    Baruch D. Kuppermann

Authors
  1. Ashish Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nilesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikulaa Parachuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anat Loewenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baruch D. Kuppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS: conception, analysis, drafting, integrity check, final approval NK, NP, FB, AL, BDK; drafting, revision, analysis, integrity check.

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Competing interests

Dr Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Dr Francesco Bandello: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. Dr Anat Loewenstein reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. Dr Baruch D Kuppermann: CLINICAL RESEARCH: Apellis, Genentech Inc, Boehringer Ingelheim, EyePoint, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio; CONSULTANT: Aviceda, Allegro Ophthalmics, Allergan/AbbVie, Bausch+Lomb, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, EyePoint, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Mobius, Neurotech Pharmaceuticals, Novartis Pharmaceuticals, Ocular Therapeutix, Outlook Therapeutics, Regeneron Pharmaceuticals Inc, ReVana Therapeutics, Ripple Therapeutics, Stealth Biotherapeutics, TechImmune, Theravance Biopharma, Visgenx. Dr Nilesh Kumar: None. Dr Nikulaa Parachuri: None.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Kumar, N., Parachuri, N. et al. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (2024). https://doi.org/10.1038/s41433-024-03001-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41433-024-03001-8

  • Springer Nature Limited

Search

Navigation